In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on Viveve Medical Inc (NASDAQ: VIVE), with a price target of $9. The company’s shares opened today at $3.01.
Vendetti wrote:
“Market open, VIVE reported preliminary 2Q18 revenue that was above both our estimate and consensus. The company also reiterated full-year 2018 revenue guidance. VIVE announced a partnership with Aesthetic Management Partners (AMP) to sell the the US through about 20 AMP sales reps. The company plans to report full 2Q18 results on August 9, 2018.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 12.0% and a 58.5% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.
Viveve Medical Inc has an analyst consensus of Strong Buy, with a price target consensus of $7, which is a 132.6% upside from current levels. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $4 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.73 and a one-year low of $1.60. Currently, Viveve Medical Inc has an average volume of 588K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Englewood, CO.
